Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland.
B.1.1.7
COVID-19
Pandemic
SARS-CoV-2
Transmission advantage
Journal
Epidemics
ISSN: 1878-0067
Titre abrégé: Epidemics
Pays: Netherlands
ID NLM: 101484711
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
01
04
2021
revised:
30
05
2021
accepted:
15
06
2021
pubmed:
7
9
2021
medline:
21
12
2021
entrez:
6
9
2021
Statut:
ppublish
Résumé
In December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) which is now named B.1.1.7. Based on initial data from the UK and later data from other countries, this variant was estimated to have a transmission fitness advantage of around 40-80 % (Volz et al., 2021; Leung et al., 2021; Davies et al., 2021). This study aims to estimate the transmission fitness advantage and the effective reproductive number of B.1.1.7 through time based on data from Switzerland. We generated whole genome sequences from 11.8 % of all confirmed SARS-CoV-2 cases in Switzerland between 14 December 2020 and 11 March 2021. Based on these data, we determine the daily frequency of the B.1.1.7 variant and quantify the variant's transmission fitness advantage on a national and a regional scale. We estimate B.1.1.7 had a transmission fitness advantage of 43-52 % compared to the other variants circulating in Switzerland during the study period. Further, we estimate B.1.1.7 had a reproductive number above 1 from 01 January 2021 until the end of the study period, compared to below 1 for the other variants. Specifically, we estimate the reproductive number for B.1.1.7 was 1.24 [1.07-1.41] from 01 January until 17 January 2021 and 1.18 [1.06-1.30] from 18 January until 01 March 2021 based on the whole genome sequencing data. From 10 March to 16 March 2021, once B.1.1.7 was dominant, we estimate the reproductive number was 1.14 [1.00-1.26] based on all confirmed cases. For reference, Switzerland applied more non-pharmaceutical interventions to combat SARS-CoV-2 on 18 January 2021 and lifted some measures again on 01 March 2021. The observed increase in B.1.1.7 frequency in Switzerland during the study period is as expected based on observations in the UK. In absolute numbers, B.1.1.7 increased exponentially with an estimated doubling time of around 2-3.5 weeks. To monitor the ongoing spread of B.1.1.7, our plots are available online.
Sections du résumé
BACKGROUND
In December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) which is now named B.1.1.7. Based on initial data from the UK and later data from other countries, this variant was estimated to have a transmission fitness advantage of around 40-80 % (Volz et al., 2021; Leung et al., 2021; Davies et al., 2021).
AIM
This study aims to estimate the transmission fitness advantage and the effective reproductive number of B.1.1.7 through time based on data from Switzerland.
METHODS
We generated whole genome sequences from 11.8 % of all confirmed SARS-CoV-2 cases in Switzerland between 14 December 2020 and 11 March 2021. Based on these data, we determine the daily frequency of the B.1.1.7 variant and quantify the variant's transmission fitness advantage on a national and a regional scale.
RESULTS
We estimate B.1.1.7 had a transmission fitness advantage of 43-52 % compared to the other variants circulating in Switzerland during the study period. Further, we estimate B.1.1.7 had a reproductive number above 1 from 01 January 2021 until the end of the study period, compared to below 1 for the other variants. Specifically, we estimate the reproductive number for B.1.1.7 was 1.24 [1.07-1.41] from 01 January until 17 January 2021 and 1.18 [1.06-1.30] from 18 January until 01 March 2021 based on the whole genome sequencing data. From 10 March to 16 March 2021, once B.1.1.7 was dominant, we estimate the reproductive number was 1.14 [1.00-1.26] based on all confirmed cases. For reference, Switzerland applied more non-pharmaceutical interventions to combat SARS-CoV-2 on 18 January 2021 and lifted some measures again on 01 March 2021.
CONCLUSION
The observed increase in B.1.1.7 frequency in Switzerland during the study period is as expected based on observations in the UK. In absolute numbers, B.1.1.7 increased exponentially with an estimated doubling time of around 2-3.5 weeks. To monitor the ongoing spread of B.1.1.7, our plots are available online.
Identifiants
pubmed: 34488035
pii: S1755-4365(21)00033-5
doi: 10.1016/j.epidem.2021.100480
pmc: PMC8452947
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100480Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.
Références
Biol Lett. 2011 Apr 23;7(2):210-3
pubmed: 20810425
PLoS Pathog. 2021 Mar 19;17(3):e1009374
pubmed: 33740028
Microorganisms. 2021 Mar 25;9(4):
pubmed: 33806013
Epidemics. 2021 Dec;37:100480
pubmed: 34488035
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
Euro Surveill. 2021 Jan;26(1):
pubmed: 33413740
Bioinformatics. 2021 Jan 20;:
pubmed: 33471068
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
Nature. 2021 Jul;595(7869):707-712
pubmed: 34098568
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Elife. 2022 Aug 08;11:
pubmed: 35938911
Proc Natl Acad Sci U S A. 2021 Mar 2;118(9):
pubmed: 33571105
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Am J Epidemiol. 2013 Nov 1;178(9):1505-12
pubmed: 24043437